NM
IOVA icon

Newtyn Management’s Iovance Biotherapeutics IOVA Stock Holding History

Newtyn Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-105,000
Closed -$642K – 63
2023
Q1 		$642K Sell
105,000
-15,000
-13% -$103K 0.13% 65
2022
Q4 		$767K Buy
120,000
+15,000
+14% +$117K 0.16% 59
2022
Q3 		$1.01M Hold
105,000
– – 0.22% 55
2022
Q2 		$1.16M Buy
+105,000
New +$1.38M 0.22% 59

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Newtyn Management's IOVA Position: Q2 2023 in Review

Newtyn Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2023, closing a stake of 105,000 shares — an estimated $642K sold.

Newtyn Management first reported a position in IOVA in Q2 2022 and held it in 4 quarters. The position peaked at $1.16M in Q2 2022. 219 funds tracked by Wall St. Rank hold IOVA as of Q2 2023.

  • Newtyn Management reported no remaining Iovance Biotherapeutics position as of Q2 2023 after selling out during the quarter.
  • Newtyn Management sold 105,000 Iovance Biotherapeutics shares in Q2 2023, an estimated $642K.
  • Newtyn Management first reported a position in Iovance Biotherapeutics in Q2 2022 and held it in 4 quarters.
  • Newtyn Management's Iovance Biotherapeutics position peaked at $1.16M in Q2 2022.
  • 219 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2023.

Based on Newtyn Management's 13F filing for Q2 2023, filed 14 Aug 2023.